Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Vivek K Srigadha"'
Autor:
Vivek K Srigadha, Kumar Prabhash, Vanita Noronha, Amit Joshi, Vijay M Patil, Nandini Menon, Ajay K Singh, Minit Shah
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 6, Iss 1, Pp 74-87 (2023)
Cabozantinib is a tyrosine kinase inhibitor that has been approved as therapy for several solid tumors, including metastatic renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. To prepare this review, we comprehensively
Externí odkaz:
https://doaj.org/article/60dbfe1f74954885a9c291f2b9902830